ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
A Prospective, Observational Study in Patients With Late-Onset Pompe Disease

This study has been completed.

Sponsored by: Genzyme
Information provided by: Genzyme
ClinicalTrials.gov Identifier: NCT00077662
  Purpose

Pompe disease (also known as glycogen storage disease type II, "GSD-II") is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes. In patients with Pompe disease, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function.

This study is being conducted to collect prospective, observational data on patients with late-onset Pompe disease. Approximately 60 subjects with late-onset Pompe disease will be enrolled.


Condition
Glycogen Storage Disease Type II

Genetics Home Reference related topics:   Pompe disease   

Drug Information available for:   Glucan 1,4-alpha-Glucosidase   

U.S. FDA Resources

Study Type:   Observational
Study Design:   Prospective
Official Title:   A Prospective, Observational Study in Patients With Late-Onset Pompe Disease

Further study details as provided by Genzyme:

Estimated Enrollment:   60

  Eligibility
Ages Eligible for Study:   8 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • The patient must provide signed, informed consent prior to performing any study-related procedures.
  • The patient must have a diagnosis of Pompe disease based upon: a) documented marked deficiency of GAA activity by muscle biopsy, skin fibroblasts, or leukocytes OR b) documented GAA gene mutation by deoxyribonucleic acid (DNA) analysis
  • The patient must be greater than 8 years of age if enrolled at a site in the U.S. and greater than 18 years of age if enrolled at a site in Europe
  • The patient must have documented onset of symptoms of Pompe disease after 12 months of age
  • The patient must have at least 3 testable muscle groups in the arms and 3 testable muscle groups in the legs using quantitative muscle testing
  • The patient must be able to perform pulmonary and muscle function testing in the supine position
  • The patient must be able to provide reproducible muscle and pulmonary function test results within 10% of each other performed on Day 1 and Day 2 of the Screening/Baseline visit and forced vital capacity measurements within 10% of each other performed in the upright position on Day 1 and Day 2 of the Screening/Baseline visit
  • The patient must have the ability to comply with the clinical protocol

Exclusion Criteria:

  • The patient is unable to ambulate (use of assistive devices, such as walker, cane, crutches, is permitted);
  • The patient requires the use of invasive ventilatory support.
  • The patient requires the use of noninvasive ventilatory support during waking hours.
  • The patient has received enzyme replacement therapy with acid alpha-glucosidase from any source
  • The patient has received an investigational drug within 30 days prior to study enrollment, or is currently enrolled in another study which involves clinical evaluations
  • The patient has a medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance including all prescribed evaluations and follow-up activities
  • The patient has a major congenital abnormality
  • For female patients only, the patient is pregnant or lactating, or is unwilling to practice birth control methods during the course of the study
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00077662

Locations
United States, District of Columbia
Children's Hospital Medical Center    
      Washington, District of Columbia, United States, 20010
United States, Missouri
School of Medicine, Campus Box 8111    
      St. Louis, Missouri, United States, 63110
United States, Washington
Children's Hospital & Regional Medical Center    
      Seattle, Washington, United States, 98105
France
Institut de Myologie, Groupe Hospitalier Pitie-Salpetriere, Batimant Babinski    
      Paris 75651, France, CEDEX 13
Netherlands
Universitair Medisch Centrum    
      Utrecht, Netherlands, 3584CX

Sponsors and Collaborators
Genzyme
  More Information


US FDA Approved Full Prescribing Information for Myozyme®  This link exits the ClinicalTrials.gov site
 

Study ID Numbers:   AGLU02303, "LOPOS"
First Received:   February 10, 2004
Last Updated:   October 21, 2008
ClinicalTrials.gov Identifier:   NCT00077662
Health Authority:   United States: Food and Drug Administration

Keywords provided by Genzyme:
Pompe Disease  
Glycogen Storage Disease Type II  
GSD-II  
Acid Maltase Deficiency Disease  
Glycogenosis 2  

Study placed in the following topic categories:
Metabolic Diseases
Glycogen Storage Disease
Lysosomal Storage Diseases
Central Nervous System Diseases
Glycogen Storage Disease Type II
Brain Diseases
Glycogen storage disease type 2
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Brain Diseases, Metabolic, Inborn
Metabolic disorder
Deficiency Diseases
Brain Diseases, Metabolic

Additional relevant MeSH terms:
Lysosomal Storage Diseases, Nervous System
Nervous System Diseases
Carbohydrate Metabolism, Inborn Errors

ClinicalTrials.gov processed this record on November 30, 2008




Links to all studies - primarily for crawlers